Posted by Michael Wonder on 27 Jun 2024
Carisma Therapeutics granted FDA fast track designation for CT-0525 for the treatment of HER2 overexpressing solid tumours
25 June 2024 - Initial Phase 1 data expected by year end 2024.
Carisma Therapeutics announced today that the US FDA has granted fast track designation for CT-0525, an ex vivo gene modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumours that overexpress human epidermal growth factor receptor 2.
